Prevalence of Overt Metastases in Locally Advanced Breast Cancer

Clinical Oncology

Volumn 20, Issue 5, 2008, Pages 340-344

  Al Husaini, H ^a   Amir, E ^a   Fitzgerald, B ^a   Wright, F ^b   Dent, R ^b   Fralick, J ^b   Clemons, M ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

Imaging; locally advanced breast cancer; metastases; staging

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE METASTASIS; BONE RADIOGRAPHY; BONE SCINTISCANNING; BREAST CANCER; CANADA; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER RELAPSE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; ECHOGRAPHY; FEMALE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM LYMPH NODE; MEDICAL RECORD REVIEW; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; SYMPTOMATOLOGY; THORAX RADIOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CANADA; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREVALENCE; RETROSPECTIVE STUDIES;

EID: 43049164293     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2008.03.006     Document Type: Article

References (13)

1. Canadian Cancer Statistics. Available from:. www.cancer.ca [accessed 19.10.07]
2. In: Greene F., Page D.L., and Fleming I.D. (Eds). AJCC cancer staging manual. 6th edn (2002), Springer, New York
3. Chen A.M., Meric-Bernstam F., Hunt K.K., et al. Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol 22 (2004) 2303-2312
4. von Minckwitz G., Raab G., Caputo A., et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 23 (2005) 2676-2685
5. Kuerer H.M., Newman L.A., Smith T.L., et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17 (1999) 460-469
6. Gonzalez-Angulo A.M., McGuire S.E., Buchholz T.A., et al. Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol 23 (2005) 7098-7104
7. Myers R.E., Johnston M., Pritchard K., Levine M., and Oliver T. Breast Cancer Disease Site Group of the Cancer Care Ontario Practice Guidelines Initiative. Baseline staging tests in primary breast cancer: a practice guideline. Can Med Assoc J 164 (2001) 1439-1444
8. Puglisi F., Follador A., Minisini A.M., et al. Baseline staging tests after a new diagnosis of breast cancer: further evidence of their limited indications. Ann Oncol 16 (2005) 263-266
9. McWhirter E., Yogendran G., Wright F., Pharm G.D., and Clemons M. Cancer Care Ontario Practice Guidelines Initiative. Baseline radiological staging in primary breast cancer: impact of educational interventions on adherence to published guidelines. J Eval Clin Pract 13 (2007) 647-650
10. Hance K.W., Anderson W.F., Devesa S.S., Young H.A., and Levine P.H. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 97 (2005) 966-975
11. Mogavero G.T., Fishman E.K., and Kuhlman J.E. Inflammatory breast cancer: CT evaluation. Clin Imaging 16 (1992) 183-186
12. Alix-Panabières C., Müller V., and Pantel K. Current status in human breast cancer micrometastasis. Curr Opin Oncol 19 (2007) 558-563
13. Landheer M.L., Steffens M.G., Klinkenbijl J.H., Westenberg A.H., and Oyen W.J. Value of fluorodeoxyglucose positron emission tomography in women with breast cancer. Br J Surg 92 (2005) 1363-1367